LOCATION   » Cancer News
LEARN      

Latest Cancer News

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Arimidex

03/9/2010

Among postmenopausal women with early, hormone receptor-positive breast cancer treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole), the Oncotype DX test predicts the risk of distant cancer recurrence in both node-negative and node-positive patients. These results were published... Continue Reading

Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer

03/9/2010

The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according to the results of a study presented at the... Continue Reading

PCA3 Test May Help Guide Prostate Biopsy Decisions

03/8/2010

The PCA3 urine test may help guide decisions about the need for repeat prostate biopsy in men with a negative initial biopsy but elevated PSA. These results were presented at the 2010 ASCO Genitourinary Cancer Symposium. Since the late 1980s, the primary screening tool for early detection of prostate... Continue Reading

Bisphosphonates May Reduce the Risk of Breast Cancer

03/8/2010

Use of bisphosphonates to treat osteoporosis may reduce the risk of breast cancer. The results of this study were published in the British Journal of Cancer. Bisphosphonates are a class of drugs used to prevent and treat osteoporosis and to reduce the risk of bone complications from bone metastases... Continue Reading

Cabazitaxel Shows Promise in Advanced Prostate Cancer

03/5/2010

Among men with metastatic, hormone refractory prostate cancer that has progressed after Taxotere® (docetaxel)-based chemotherapy, the investigational chemotherapy drug cabazitaxel may improve survival. The results of this Phase III clinical trial will be presented at the ASCO 2010 Genitourinary... Continue Reading

Benefit of Velcade on Myeloma Survival Added to Prescribing Information

03/5/2010

The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients with previously untreated multiple myeloma. Multiple... Continue Reading

Cervical Vaccine Provides Little Benefit for Older Women

03/4/2010

Women over the age of 40 are not likely to benefit from a vaccine designed to prevent human papillomavirus (HPV), according to the results of a study published in the Journal of the National Cancer Institute.1 HPV has been shown to cause cervical cancer. Human papillomaviruses consist of more than... Continue Reading

Tykerb plus Herceptin More Effective Than Tykerb Alone for Metastatic Breast Cancer That Has Progressed on Herceptin

03/3/2010

Among women with HER2-positive, metastatic breast cancer that has progressed during treatment with Herceptin® (trastuzumab), the combination of Tykerb® (lapatinib) and Herceptin appears to be more effective than Tykerb alone. These results were published in the Journal of Clinical Oncology and... Continue Reading

Abiraterone Produces Promising Results in Men with Hormone Refractory Prostate Cancer

03/2/2010

According to the results of Phase II clinical trials, the investigational drug abiraterone appears to be active in men with hormone refractory prostate cancer (HRPC). These results were published in the Journal of Clinical Oncology. Current treatment options for prostate cancer include watchful waiting,... Continue Reading

Avastin May Delay Progression of Ovarian Cancer

02/25/2010

Among women with advanced ovarian cancer, treatment with a combination of Avastin® (bevacizumab) and chemotherapy, followed by maintenance treatment with Avastin, may result in better progression-free survival than chemotherapy alone. Initial results of this Phase III clinical trial were made available... Continue Reading

Avastin Fails to Prolong Survival in Stomach Cancer

02/25/2010

Avastin® (bevacizumab) in combination with chemotherapy does not extend overall survival in patients with inoperable, advanced or metastatic stomach cancer, according to the results of a phase III trial released by Roche.[i] Stomach cancer, also known as gastric cancer, has limited treatment options.... Continue Reading

Afinitor and Temodar Active against Pancreatic Neuroendocrine Tumors

02/24/2010

The combination of Afinitor® (everolimus) and Temodar® (temozolomide) appears to be active against advanced pancreatic neuroendocrine tumors. The details of this Phase I/II study were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.[1] Neuroendocrine... Continue Reading

Next Page »